1-10 of 10
William C Shakespeare
Close
Sort by
Journal Articles

Discovery of Potent and Selective Next-Generation Pan-BCR-ABL Inhibitors for the Treatment of CML and Ph+ ALL

Yun Zhang, Sara Nadworny, Shengwu Liu, Sen Zhang, Emily Ye, Narayana Narasimhan, David C Dalgarno, Justin Pritchard, Wei-Sheng Huang, William C Shakespeare, Victor M Rivera
Journal: Blood
Blood (2023) 142 (Supplement 1): 1428.
https://doi.org/10.1182/blood-2023-172982
Published: 2023
Journal Articles

Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor

Thomas O’Hare, Christopher A. Eide, Lauren T. Adrian, Victor M. Rivera, William C. Shakespeare, Tim Clackson, Michael W. N. Deininger, Brian J. Druker
Journal: Blood
Blood (2008) 112 (11): 726.
https://doi.org/10.1182/blood.V112.11.726.726
Published: 2008
Journal Articles

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

Victor M. Rivera, PhD, Qihong Xu, PhD, Lori Berk, Jeffrey Keats, Scott Wardwell, Frank Wang, PhD, William C. Shakespeare, PhD, Tim Clackson, PhD
Journal: Blood
Blood (2008) 112 (11): 2932.
https://doi.org/10.1182/blood.V112.11.2932.2932
Published: 2008
Journal Articles

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Victor M. Rivera, PhD, Qihong Xu, PhD, Frank Wang, PhD, Joseph Snodgrass, PhD, Thomas O’Hare, PhD, Amie S. Corbin, Jeffrey Keats, Sarah Lamore, Yaoyu Ning, Scott Wardwell, Karin Russian, Marc Broudy, William C. Shakespeare, PhD, Brian J. Druker, MD, John D. Iuliucci, PhD, Tim Clackson, PhD
Journal: Blood
Blood (2007) 110 (11): 1032.
https://doi.org/10.1182/blood.V110.11.1032.1032
Published: 2007
Journal Articles

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

William C. Shakespeare, PhD, Frank Wang, Ph.D., Qihong Xu, Ph.D., Xiaotian Zhu, Ph.D., Narayana Narasimham, Ph.D., Chester A. Metcalf, Ph.D., Yihan Wang, Ph.D., Raji Sundaramoorthi, Ph.D., Wei-Sheng Huang, Ph.D., Dong Zou, Ph.D., Mathew Thomas, Ph.D., Jan Romero, Ph.D., David Wen, M.S., Ingrid Chen, B.S., Lisi Cai, M.S., Shuangying Liu, M.S., Scott Wardwell, B.S., Yaoyu Ning, M.S., Jeff Keats, B.S., Joseph Snodgrass, Ph.D., Karin Russian, M.S., Marc Broudy, B.S., Thomas O’Hare, Ph.D., Caitlyn Smith, B.S., Amie Corbin, Ph.D., Brian Druker, M.D., John Iuliucci, Ph.D., David Dalgarno, Ph.D., Tomi K. Sawyer, Ph.D., Tim Clackson, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2180.
https://doi.org/10.1182/blood.V108.11.2180.2180
Published: 2006
Journal Articles

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

Mohammad Azam, PhD, William C. Shakespeare, PhD, Chester Metcalf, PhD, Yihan Wang, PhD, Raji Sunderamoorthi, PhD, Xiaotan Zhu, PhD, Wei-Sheng Huang, PhD, Dong Zou, PhD, Mathew Thomas, PhD, Jan Romero, PhD, Jeff Keats, PhD, Qihang Xu, PhD, David Dalgarno, PhD, Tim Clackson, PhD, Tomi K. Sawyer, PhD, George Q. Daley, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2181.
https://doi.org/10.1182/blood.V108.11.2181.2181
Published: 2006
Journal Articles

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, III, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian J. Druker, Michael W. N. Deininger
Journal: Blood
Blood (2005) 106 (1): 227–234.
https://doi.org/10.1182/blood-2004-12-4771
Published: 2005
Includes: Supplemental data
Journal Articles

A Potent Src/Abl Kinase Inhibitor (Ap23464) Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by Flt3-Itd Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an Abl-Independent Mechanism.

Jukka Kanerva, MD, PhD, Ogonna Nwawka, BS, Kevin Hwang, William C. Shakespeare, PhD, Chester A. Metcalf, III, PhD, Tomi K. Sawyer, PhD, Camille L. Bedrosian, MD, Seth J. Corey, MD
Journal: Blood
Blood (2004) 104 (11): 4479.
https://doi.org/10.1182/blood.V104.11.4479.4479
Published: 2004
Journal Articles

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Chester A. Metcalf, III, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David C. Dalgarno, John Iuliucci, Tomi K. Sawyer, Brian J. Druker, Michael W. Deininger
Journal: Blood
Blood (2004) 104 (11): 793.
https://doi.org/10.1182/blood.V104.11.793.793
Published: 2004
Journal Articles

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O'Hare, Roy Pollock, Eric P. Stoffregen, Jeffrey A. Keats, Omar M. Abdullah, Erika M. Moseson, Victor M. Rivera, Hao Tang, Chester A. Metcalf, III, Regine S. Bohacek, Yihan Wang, Raji Sundaramoorthi, William C. Shakespeare, David Dalgarno, Tim Clackson, Tomi K. Sawyer, Michael W. Deininger, Brian J. Druker
Journal: Blood
Blood (2004) 104 (8): 2532–2539.
https://doi.org/10.1182/blood-2004-05-1851
Published: 2004